跳至主要内容
临床试验/NCT00116467
NCT00116467已完成2 期

Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia: The Use of Autologous Tumor Cells With an Allogeneic GM-CSF Producing Cell Line

Cell Genesys4 个研究点 分布在 1 个国家目标入组 55 人开始时间: 2001年3月1日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
55
试验地点
4

研究概览

简要总结

The purpose of this study is to evaluate clinical and laboratory safety associated with the administration of GVAX leukemia vaccine and to determine the feasibility of generation of GVAX leukemia vaccine in subjects with acute myelogenous leukemia (AML).

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Initial diagnosis of de novo AML with no preexisting hematologic dysplasia for more than 3 months.
  • •No prior therapy except leukapheresis or less than 72 hours of hydroxyurea.

排除标准

  • •Prior myelodysplastic disorder, or treatment-related leukemia.
  • •Prior myeloproliferative disease.
  • •Acute promyelocytic leukemia (APL).
  • •Prior chemotherapy for a malignant or nonmalignant disorder.

研究者

发起方
Cell Genesys
申办方类型
Industry

研究点 (4)

Loading locations...

相似试验

Vaccination in the Peripheral Stem Cell Transplant... | 临床试验